

# Behcet Disease - Pipeline Review, H1 2020

<https://marketpublishers.com/r/BF054E1C19FEN.html>

Date: April 2020

Pages: 65

Price: US\$ 2,000.00 (Single User License)

ID: BF054E1C19FEN

## Abstracts

Behcet Disease - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2020, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.

'Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems.'

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Behcet Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Behcet Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Behcet Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 2 respectively.

Behcet Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Behcet Disease (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Behcet Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Behcet Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Behcet Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Behcet Disease (Cardiovascular)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Behcet Disease (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Behcet Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Behcet Disease - Overview
- Behcet Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Behcet Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Behcet Disease - Companies Involved in Therapeutics Development
- Amgen Inc
- GlaxoSmithKline Plc
- Iltoo Pharma
- InSight Biopharmaceuticals Ltd
- Novartis AG
- Pharmapraxix
- R Pharm
- Silk Road Therapeutics
- Behcet Disease - Drug Profiles
- adalimumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- adalimumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- aldesleukin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- apremilast - Drug Profile
- Product Description
- Mechanism Of Action

## R&D Progress

canakinumab - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

GSK-1070806 - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

pentoxifylline - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

RPH-104 - Drug Profile

Product Description

Mechanism Of Action

## R&D Progress

Behcet Disease - Dormant Projects

Behcet Disease - Discontinued Products

Behcet Disease - Product Development Milestones

Featured News & Press Releases

Feb 27, 2020: CHMP recommended extensions of indication for Otezla

Jul 19, 2019: FDA approves OTEZLA (apremilast) for the treatment of oral ulcers associated with Behcet's Disease

Feb 17, 2018: OTEZLA (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behcet's Disease with Oral Ulcers

Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir

Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet

Apr 15, 2015: Phase II Data for Apremilast in Behcet's Disease Published in The New England Journal of Medicine

Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behcet's Disease At EULAR

## Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)  
[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Behcet Disease, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Behcet Disease - Pipeline by Amgen Inc, H1 2020

Behcet Disease - Pipeline by GlaxoSmithKline Plc, H1 2020

Behcet Disease - Pipeline by Iltoo Pharma, H1 2020

Behcet Disease - Pipeline by InSight Biopharmaceuticals Ltd, H1 2020

Behcet Disease - Pipeline by Novartis AG, H1 2020

Behcet Disease - Pipeline by Pharmapraxis, H1 2020

Behcet Disease - Pipeline by R Pharm, H1 2020

Behcet Disease - Pipeline by Silk Road Therapeutics, H1 2020

Behcet Disease - Dormant Projects, H1 2020

Behcet Disease - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Behcet Disease, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Targets, H1 2020  
Number of Products by Stage and Targets, H1 2020  
Number of Products by Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Amgen Inc  
GlaxoSmithKline Plc  
Iltoo Pharma  
InSight Biopharmaceuticals Ltd  
Novartis AG  
Pharmapraxis  
R Pharm  
Silk Road Therapeutics



## I would like to order

Product name: Behcet Disease - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/BF054E1C19FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BF054E1C19FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970